We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Use of Omega-3 Fatty Acid Supplements Has Insufficient Clinical Evidence for Treatment of Hypertriglyceridemia: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials.
- Authors
Nam, Gina E.; Myung, Seung‐Kwon; Choi, Yoon‐Jung
- Abstract
Omega-3 fatty acid supplements have been used to treat dyslipidemia. However, there is no comprehensive meta-analysis of randomized, double-blind, placebo-controlled trials that encompasses a broad range of populations with or without underlying diseases regarding their efficacy. PubMed, EMBASE, and Cochrane Library were searched for trials in June 2016. A pooled weighted mean difference with its 95% confidence interval (CI) was calculated using a random-effect meta-analysis. A total of 58 trials were included in the final analysis. Compared with placebos, omega-3 fatty acid supplements significantly reduced triglyceride (TG) levels by 38.59 mg dL−1 (95%CI, −47.16 to −30.02 mg dL−1; n = 53). In the subgroup meta-analysis, the beneficial effects on TG levels were dose-dependent up to 3.9 g of omega-3 fatty acid supplements daily and were greater at higher baseline TG levels. However, there existed substantial heterogeneity in the main and subgroup meta-analyses, overall methodological quality of included trials were low, and about 70% of the included trials had a small sample size less than 100 participants. The current meta-analysis of randomized, double-blind, placebo-controlled trials suggests that there is no sufficient clinical evidence to support the use of omega-3 fatty acid supplements for the prevention or treatment of dyslipidemia. Practical Applications: Further large, high-quality randomized, double-blind, placebo-controlled trials with a long-term follow-up are warranted to confirm the clinical efficacy of omega-3 fatty acid supplements on lipid profiles management. The meta-analysis of 53 randomized, double-blind, placebo-controlled trials shows a beneficial effect of omega-3 fatty acid supplements such as EPA and DHA on triglyceride levels. However, there exists substantial heterogeneity in the main and subgroup meta-analyses, overall methodological quality of includes trials was low, and about 70% of the include trials has a small sample size less than 100 participants. WMD, weighted mean difference; CI, confidence interval.
- Subjects
DYSLIPIDEMIA; OMEGA-3 fatty acids; TRIGLYCERIDES; RANDOMIZED controlled trials; RANDOM effects model; THERAPEUTICS
- Publication
European Journal of Lipid Science & Technology, 2017, Vol 119, Issue 12, pn/a
- ISSN
1438-7697
- Publication type
Article
- DOI
10.1002/ejlt.201700111